Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination

Gene Therapy

Volumn 4, Issue 10, 1997, Pages 1069-1076

  Bramson, J L ^a   Hitt, M ^a   Gauldie, J ^a   Graham, F L ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Adenovirus; Dissemination; Tumor immunotherapy

Indexed keywords

INTERLEUKIN 12; TUMOR ANTIGEN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TUMOR REGRESSION; VIRUS IMMUNITY;

ADENOVIRIDAE; ANIMALIA;

EID: 0030774216     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300508     Document Type: Article

References (25)

1. Hitt M, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. In: August T et al (eds). Gene Therapy (Advances in Pharmacology, vol. 40) Academic Press: San Diego, 1997, pp 137-206.
2. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
3. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
4. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
5. Gilgenkrantz H et al. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther 1995; 6: 1265-1274.
6. Addison CL et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
7. Addison CL, Gauldie J, Muller WJ, Graham FL. An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model. Int J Oncol 1995; 7: 1253-1260.
8. Bramson J et al. Direct intratumoral injection of an adenovirus expressing IL-12 induces regression and long-lasting immunity which is associated with highly localized expression of IL-12. Hum Gene Ther 1996; 7: 1995-2002.
9. Chen S-H et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
10. Hirschowitz EA et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055-1063.
11. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyoma middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
12. Huard J et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy 1995; 2: 107-115.
13. Mittal SK et al Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 1993; 28: 67-90.
14. Toloza EM et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996; 3: 11-17.
15. Wan Y et al. Dendritic cells transduced with an adenovirus vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8: 1355-1360.
16. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736.
17. Fisher KJ et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virol 1996; 217: 11-22.
18. Parks RJ et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
19. Hardy S et al. Construction of adenovirus vectors through Crelox recombination. J Virol 1997; 71: 1842-1849.
20. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus 5. J Gen Virol 1977; 36: 59-72.
21. Hitt M, Bett AJ, Prevec L, Graham FL. Construction and propagation of human adenovirus vectors: In: Celis JE (ed). Cell Biology. A Laboratory Handbook. Academic Press: San Diego, 1994, pp 479-490.
22. Bramson J et al. Construction of a double recombinant adeno-virus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996; 7: 333-342
23. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-6806.
24. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653-1661.
25. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.